“Malignant” Perivascular Epithelioid Cell Neoplasm: Risk Stratification and Treatment Strategies
Sarcoma · 2012 · 2012 · 1-12
DOI: 10.1155/2012/541626 ↗Kurz gefasst
Fachartikel in der Zeitschrift Sarcoma, 2012. Verfasst von Jonathan S Bleeker und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Medical Oncology, Department of Oncology, Mayo Clinic, Rochester, MN 55905, USA. Die Arbeit wurde bisher 187-mal zitiert (Crossref) und nennt 82 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 3.0). Gefördert von: NCRR NIH HHS, National Center for Research Resources.
Abstract (Originalsprache)
Purpose
Perivascular epithelioid cell tumors (PEComas) are a rare collection of tumors characterized by a myomelanocytic phenotype, and PEComas occurring in “nonclassic” anatomic distributions are known as perivascular epithelioid cell tumor not otherwise specified (PEComa-NOS). This review aims to compile and analyze cases of PEComa-NOS in an effort to better define their natural history.
Design
We evaluated all 234 cases of PEComa-NOS reported in the English literature, extracting information regarding diagnostic features, treatment approaches, and outcomes. Multivariate analysis of a number of variables evaluable on pathologic review was performed to refine preexisting risk stratification criteria. Outcomes for patients receiving nonsurgical treatment are also reported.
Results
Primary tumor size ≥5 cm ( P = 0.02 ) and a high (1/50 HPF) mitotic rate ( P < 0.0001 ) were the only factors significantly associated with recurrence following surgical resection. Cytotoxic chemotherapy and radiation therapy have shown little benefit in treating PEComa-NOS; mTOR inhibition is emerging as a treatment option.
Conclusion
Progress has been made in understanding the natural history and molecular biology of PEComa-NOS. This review further clarifies risk of recurrence in this disease, allowing clinicians to better risk stratify patients. Further work should focus on applying this knowledge to making treatment decisions for patients with this disease.
Autor:innen und Institutionen
- Division of Medical Oncology, Department of Oncology, Mayo Clinic, Rochester, MN 55905, USA.
Förderung
- NCRR NIH HHS
- National Center for Research Resources
Zitieren
APA
Bleeker, J. S., Quevedo, J. F., & Folpe, A. L. (2012). “Malignant” Perivascular Epithelioid Cell Neoplasm: Risk Stratification and Treatment Strategies. Sarcoma, 2012, 1-12. https://doi.org/10.1155/2012/541626
Vancouver
Bleeker JS, Quevedo JF, Folpe AL. “Malignant” Perivascular Epithelioid Cell Neoplasm: Risk Stratification and Treatment Strategies. Sarcoma. 2012;2012:1-12. doi:10.1155/2012/541626
BibTeX
@article{Bleeker2012,
author = {Bleeker, Jonathan S and Quevedo, J Fernando and Folpe, Andrew L},
title = {“Malignant” Perivascular Epithelioid Cell Neoplasm: Risk Stratification and Treatment Strategies},
journal = {Sarcoma},
year = {2012},
volume = {2012},
pages = {1--12},
doi = {10.1155/2012/541626}
}
EUVIMED